A number of oral therapies are in a late stage of development for MS (Table 2). In addition to cladribine tablets, for which key data are reviewed below, oral therapies undergoing investigation in ...

Patients can switch treatment after two years if JCV antibody-index is positive. One of the alternative treatment options include a weight based adjusted cladribine tablets that have been approved for ...

Other clinical trials have tested a drug called Cladribine, a powerful intravenous chemotherapy drug used for leukemia, in Type II refractory patients. One trial, conducted in the Netherlands, found ...

Ozanimod▼ is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active ...

There are many treatments available for MS, many of which can help decrease the frequency and severity of relapses, improve physical function, and ease symptoms caused by the condition. While ...

Biogen’s multiple sclerosis franchise has been handed a boost with the US approval of Vumerity, a follow-up to its blockbuster Tecfidera that promises to be less likely to cause gastrointestinal ...

There’s no news yet on its US list price. Along with other S1P drugs, it will also have to compete with Merck KGaA’s Mavenclad (cladribine), which has a difference mechanism of action but was ...

In 2024, the Rx IP Update team at Smart & Biggar reported on a number of developments in Canadian life sciences IP and ...

The risk of bladder, brain, cervical, and kidney cancer was significantly increased in MS… A sublingual formulation of cladribine, which is the active ingredient of the approved oral treatment ...

Background A growing evidence base supports the use of autologous haematopoietic stem cell transplantation (aHSCT) for treatment of relapsing-remitting multiple sclerosis (RRMS), but it has not yet ...